Cargando…
Successful case of olaparib treatment for castration-resistant prostate cancer with multiple DNA repair gene mutations: Use of comprehensive genome profiling for treatment-refractory cases
Herein, we report a case of a 59-year-old man with advanced castration-resistant prostate cancer with rectal invasion. Multimodal treatment, including drug therapy, surgery, and radiation therapy was sequentially performed; however, lymph node metastases repeatedly occurred. Tumor genomic profiling...
Autores principales: | Hirayama, Yukiyoshi, Kato, Minoru, Kimura, Kaoru, Otoshi, Taiyo, Yamasaki, Takeshi, Uchida, Junji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460157/ https://www.ncbi.nlm.nih.gov/pubmed/36092022 http://dx.doi.org/10.1016/j.eucr.2022.102210 |
Ejemplares similares
-
Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma
por: Yamamoto, Shoma, et al.
Publicado: (2023) -
Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023) -
Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
por: Cheng, Yuan, et al.
Publicado: (2018) -
Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report
por: Zhang, Li, et al.
Publicado: (2021) -
Editorial Comment from Dr Hirayama and Dr Iguchi to Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Hirayama, Yukiyoshi, et al.
Publicado: (2021)